The detailed and damning allegations of corruption against GlaxoSmithKline’s Chinese subsidiary travel well beyond the offices of one of the world’s largest drugmakers.
“All departments and pharmaceutical production subsidiaries of GlaxoSmithKline (China) Investment were fully engaged” in bribery, an official in the economic crime investigation unit of the Ministry of Public Security said yesterday.
This was nothing short of a public statement – directed at the foreign business community in China – that the rules of engagement have fundamentally changed.
您已閱讀14%（558字），剩餘86%（3348字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。